Structure Therapeutics posts positive early data for oral weight-loss program
Structure Therapeutics reported Phase 1/2a SAD results for ACCG-2671, an oral amylin receptor agonist, citing ~6-day half-life, no serious adverse events, and target engagement including up to 3.3% body weight loss.